FindTrial
Sign In

Helping liver cancer surgery patients predict treatment efficacy in advance—A survival prediction tool for postoperative combined embolization therapy

Prognostic factors and prediction model for patients undergoing hepatectomy combined with transarterial embolization for primary hepatocellular carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117969
Enrollment
Unknown
Registered
2026-01-30
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary liver cancer

Interventions

Hepatectomy + postoperative TACE/TAE cohort:None

Sponsors

Ningbo Medical Centre Lihuili Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who underwent hepatectomy and were pathologically confirmed to have hepatocellular carcinoma; 2.First embolization treatment, administered between January 2022 and October 2025; 3.Complete clinical, laboratory, and imaging data;

Exclusion criteria

Exclusion criteria: 1. Secondary liver cancer or presence of other concurrent malignant tumors; 2.Prior embolization, ablation, radiotherapy, or systemic therapy before surgery;

Design outcomes

Primary

MeasureTime frame
Death from any cause;—

Countries

China

Contacts

Public ContactYanna Han

Ningbo Medical Centre Lihuili Hospital

523197743@qq.com+86 574 8701 8701

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026